Hemispherx BioPharma Postpones Offering Pending Annual Report Filing
Hemispherx BioPharma, trading on the NYSE American under the ticker symbol HEB, announced through its subsidiary AIM ImmunoTech Inc. that it would be delaying an offering detailed in its Registration Statement on Form S-1. This decision, disclosed in a press release on February 11, 2025, indicates that the offering will be deferred until after the […]
Hemispherx BioPharma, trading on the NYSE American under the ticker symbol HEB, announced through its subsidiary AIM ImmunoTech Inc. that it would be delaying an offering detailed in its Registration Statement on Form S-1. This decision, disclosed in a press release on February 11, 2025, indicates that the offering will be deferred until after the […]
